Alvotech (ALVO) - Total Assets
Based on the latest financial reports, Alvotech (ALVO) holds total assets worth Ikr1.41 Billion ISK (≈ $11.49 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check ALVO cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Alvotech - Total Assets Trend (2020–2024)
This chart illustrates how Alvotech's total assets have evolved over time, based on quarterly financial data. Explore Alvotech (ALVO) long-term investment share to see how much of total assets are deployed in long-term investments.
Alvotech - Asset Composition Analysis
Current Asset Composition (December 2024)
Alvotech's total assets of Ikr1.41 Billion consist of 37.3% current assets and 62.8% non-current assets.
| Asset Category | Amount (ISK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Ikr0.00 | 4.2% |
| Accounts Receivable | Ikr160.22 Million | 13.1% |
| Inventory | Ikr127.89 Million | 10.5% |
| Property, Plant & Equipment | Ikr0.00 | 0.0% |
| Intangible Assets | Ikr20.62 Million | 1.7% |
| Goodwill | Ikr11.33 Million | 0.9% |
Asset Composition Trend (2020–2024)
This chart illustrates how Alvotech's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ALVO market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alvotech's current assets represent 37.3% of total assets in 2024, an increase from 18.2% in 2020.
- Cash Position: Cash and equivalents constituted 4.2% of total assets in 2024, down from 6.7% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 3.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 13.1% of total assets.
Alvotech Competitors by Total Assets
Key competitors of Alvotech based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs585.02 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $392.01 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs8.94 Billion |
Alvotech - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.42 | 2.69 | 1.38 |
| Quick Ratio | 0.74 | 1.92 | 0.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Ikr127.94 Million | Ikr272.06 Million | Ikr63.44 Million |
Alvotech - Advanced Valuation Insights
This section examines the relationship between Alvotech's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.88 |
| Asset Growth Rate (YoY) | 28.6% |
| Total Assets | Ikr1.22 Billion |
| Market Capitalization | $1.07 Billion USD |
Valuation Analysis
Near Book Valuation: The market values Alvotech's assets close to their book value (0.88x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Alvotech's assets grew by 28.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Alvotech (2020–2024)
The table below shows the annual total assets of Alvotech from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Ikr1.22 Billion ≈ $9.96 Million |
+28.56% |
| 2023-12-31 | Ikr950.09 Million ≈ $7.75 Million |
+14.68% |
| 2022-12-31 | Ikr828.44 Million ≈ $6.75 Million |
+38.54% |
| 2021-12-31 | Ikr597.98 Million ≈ $4.88 Million |
+26.04% |
| 2020-12-31 | Ikr474.42 Million ≈ $3.87 Million |
-- |
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic art… Read more